Holen Sie sich die Stockscreener-App
10.66
1.81%
0.19
Handel nachbörslich:
10.60
-0.06
-0.56%
Schlusskurs vom Vortag:
$10.47
Offen:
$10.35
24-Stunden-Volumen:
213.76K
Relative Volume:
1.88
Marktkapitalisierung:
$524.68M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+8.22%
1M Leistung:
-23.03%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$10.17
$10.99
1-Wochen-Bereich:
$9.00
$11.24
52-Wochen-Spanne:
$9.00
$17.45
Agomab Therapeutics Nv Adr Stock (AGMB) Company Profile
Firmenname
Agomab Therapeutics Nv Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare AGMB vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AGMB
Agomab Therapeutics Nv Adr
|
10.66 | 515.33M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Agomab Therapeutics Nv Adr Stock (AGMB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-03 | Eingeleitet | JP Morgan | Overweight |
| 2026-03-03 | Eingeleitet | Leerink Partners | Outperform |
| 2026-03-03 | Eingeleitet | Morgan Stanley | Overweight |
Agomab Therapeutics Nv Adr Aktie (AGMB) Neueste Nachrichten
United Health Group, Viacom among market cap stock movers on Tuesday - Investing.com
Reviewing Prime Medicine (NASDAQ:PRME) and AgomAb Therapeutics (NASDAQ:AGMB) - Defense World
Agomab receives U.S. patent for lung fibrosis drug candidate By Investing.com - Investing.com India
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis - GlobeNewswire Inc.
Agomab receives U.S. patent for lung fibrosis drug candidate - Investing.com
Total equity of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
Total liabilities of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
Total liabilities & shareholders' equities of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
Total debt of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
AgomAb Therapeutics NV ADR Balance Sheet – DUS:M5E - TradingView
AgomAb Therapeutics NV ADR Cash Flow – DUS:M5E - TradingView
EBITDA per share of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
AgomAb Therapeutics NV ADR Income Statement – DUS:M5E - TradingView
AgomAb Therapeutics NV ADR Earnings and Revenue – DUS:M5E - TradingView
Basic earnings per share (basic EPS) of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
Free float of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
Net income of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Sahm
Total common shares outstanding of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Tangible book value per share of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Debt to assets ratio of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Cash per share of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Net current asset value per share of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Enterprise value to EBITDA ratio of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
EBITDA margin % of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Cash Flow – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Balance Sheet – TRADEGATE:M5E - TradingView
EBITDA of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Diluted earnings per share (diluted EPS) of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Non-operating income (total) of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Financial Statements – TRADEGATE:M5E - TradingView
Diluted net income available to common stockholders of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Revenue Breakdown – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Statistics – TRADEGATE:M5E - TradingView
Gross profit of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Net income before discontinued operations of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Operating income of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Total revenue of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Non-controlling/minority interest of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Income Statement – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Earnings and Revenue – TRADEGATE:M5E - TradingView
Free float of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Agomab closes $200 million IPO on NASDAQ - Investing.com India
Agomab closes $200 million IPO on NASDAQ By Investing.com - Investing.com Nigeria
EQT Life Sciences-Backed AgomAb Falls After $200 Million IPO - Mint
Agomab Therapeutics opens below IPO price in Nasdaq debut By Investing.com - Investing.com Canada
Agomab Therapeutics opens below IPO price in Nasdaq debut - Investing.com
Agomab prices IPO at $16 per share, aims to raise $200 million - Investing.com Australia
Agomab prices IPO at $16 per share, aims to raise $200 million By Investing.com - Investing.com India
symbol__ Stock Quote Price and Forecast - CNN
AGMB Stock Price and Chart — NASDAQ:AGMB - TradingView — Track All Markets
Finanzdaten der Agomab Therapeutics Nv Adr-Aktie (AGMB)
Es liegen keine Finanzdaten für Agomab Therapeutics Nv Adr (AGMB) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):